Pricing Log in Create free account

Nuvation Bio Inc. (NUVB) vs Ultragenyx Pharmaceutical Inc. (RARE)

Nuvation Bio Inc. and Ultragenyx Pharmaceutical Inc. are both Biotechnology companies. Nuvation Bio Inc. and Ultragenyx Pharmaceutical Inc. are of similar size ($1.5B and $1.5B). Nuvation Bio Inc. grew revenue faster over the last twelve months: 654.2% against 15.8%. Nuvation Bio Inc. has the higher net margin (−67.4% vs −71.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Nuvation Bio Inc. leads on 10 and Ultragenyx Pharmaceutical Inc. on 5.

Valuation

Metric NUVB RARE Biotechnology median
P/E n/m n/m 10.60
P/S 7.27 2.17 9.40
P/B 6.44 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 5.40 1.80 9.02
Earnings yield (9.44%) (33.48%) (32.88%)
Free cash flow yield (7.37%) (28.26%) (23.13%)

Profitability

Metric NUVB RARE Biotechnology median
Gross margin 85.79% 82.88% 68.51%
Operating margin (61.17%) (63.97%) 0.00%
Net margin (67.38%) (71.78%) 0.00%
Free cash flow margin (53.62%) (61.23%) 0.00%
Return on equity (49.09%) 285.68% (51.96%)
Return on assets (19.70%) (44.08%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NUVB RARE Biotechnology median
Revenue growth (TTM) 654.19% 15.75% 6.76%
EPS growth (last fiscal year) 71.56% 7.31% 29.88%
Revenue growth, 5-year CAGR — 19.95% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NUVB RARE Biotechnology median
Debt to equity 1.25 0.00 0.00
Current ratio 7.45 1.40 4.97
Net debt to EBITDA 2.26 1.35 1.01

Dividend

Metric NUVB RARE Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric NUVB RARE Biotechnology median
Market cap 1.48b 1.54b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack